Drug boosts growth in young patients with dwarfism


Tuesday, 18 June, 2019


Drug boosts growth in young patients with dwarfism

Children with a common form of dwarfism now have a chance at boosted growth rates thanks to a groundbreaking drug developed by Australian researchers.

The drug, tested in a global trial led by Melbourne’s Murdoch Children’s Research Institute, regulates bone development and boosts growth rates in children with achondroplasia — the most common type of dwarfism.

Results of the Phase 2 trial in children aged five to 14 years were recently published in the New England Journal of Medicine; Phase 3 of the project is underway to test the drug, vosoritide, in a larger group of patients aged 5 to 18 years.

Lead author and MCRI clinical geneticist Professor Ravi Savarirayan, said achondroplasia is caused by overactivity of a signal that stops growth, and could be likened to overwatering a plant. “This drug basically kinks the hose so that the plant gets the right amount of water and can resume regular growth,” Prof. Savarirayan said.

Achondroplasia is a genetic bone disorder affecting about one in every 25,000 infants. It is caused by a mutation in the FGFR3 gene that impairs the growth of bones in the limbs, the spine and the base of the skull. The most common health complications experienced by children with achondroplasia are spinal cord compression, spinal curvature and bowed legs. About half of these children will need spinal or other surgery.

“This can mean a lot of time away from school as the child recovers and rehabilitates after surgery, which can affect important social connections,” Prof. Savarirayan said.

Unlike other treatments — such as growth hormone and limb-lengthening surgery — that focus on symptoms, vosoritide focuses on the underlying cause of achondroplasia and directly counteracts the effect of the mutation that slows growth. The study ran over four years across research centres in Australia, France, UK and USA with 35 children assigned to one of four groups receiving daily subcutaneous doses of the drug in increasing amounts.

The main aims of the Phase 2 trial were to evaluate safety and tolerability of the drug and to determine the best dose for the Phase 3 trials, which are now underway.

The results showed vosoritide was generally well tolerated by patients and demonstrated dose-dependent increases in centimetres grown per year during the first six months, with improvements maintained over the study extension period of a further three years.

On average, participants in the trial grew at a 50% faster compared to baseline with no adverse effects on body proportion. Overall bone age was not accelerated, implying that this effect, if sustained long-term, might increase final adult height.

Currently, management of the medical complications of achondroplasia is predominantly surgical. A placebo-controlled trial of vosoritide in younger children aged 0 to five years that is currently underway may help researchers shed light on the effects of earlier treatment on body proportion and other age-related complications such as compression of the spinal cord as it exits the skull, which can cause sudden death in this condition if not treated.

Image credit: ©stock.adobe.com/au/ibreakstock

Related News

Opposition for Qld trial to treat UTIs with antibiotics

The Royal Australian College of General Practitioners has spoken out about a Queensland...

Drug-resistant bacteria found on hospital insects

More than 50% of bacteria recovered from flying insects in a group of English hospitals has been...

Australian pre-teens sedentary, new study finds

It's not unusual for 11- and 12-year-olds to spend up to 11 hours seated.


  • All content Copyright © 2019 Westwick-Farrow Pty Ltd